144 results about "Senescent cell" patented technology

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Disclosed are agents (e.g., peptides, polypeptides, proteins, small molecules, antibodies, and antibody fragments that target senescent cells) and methods of their use for imaging senescent cells in vivo and for treating or preventing cancer, age-related disease, tobacco-related disease, or other diseases and disorders related to or caused by cellular senescence in a mammal. The methods include administering one or more of the agents of the invention to a mammal, e.g., a human. The agents, which specifically bind to senescent cells, can be labeled with a radioactive label or a therapeutic label, e.g., a cytotoxic agent.

The present disclosure provides compositions and methods for selectively killing senescent cells, wherein the selective killing of senescent cells delays aging and treats age-related disorders.

Fibrosis arises as part of a wound healing response that maintains organ integrity following catastrophic tissue damage, but can also contribute to a variety of human pathologies, including liver cirrhosis. The invention demonstrates that cellular senescence acts to limit the fibrogenic response to tissue damage, thereby establishing a role for the senescence program in pathophysiological settings beyond cancer. Accordingly, the methods of the invention relate to modulating cellular senescence in disease tissue that have elevated numbers of senescent cells, such as in fibrotic tissues.

Provided herein are methods and uses for treatment or prophylaxis of a senescent cell associated disease or disorder by administering a senolytic combination comprising dasatinib and quercetin or an analog thereof to a subject in need thereof. In certain embodiments, the senescent cell associated disease or disorder is a cardiovascular disease or disorder, inflammatory disease or disorder, a pulmonary disease or disorder, a neurological disease or disorder, or a metabolic disease or disorder.

The invention relates to a method for reprogramming cells from aged donors or senescent cells to pluripotent cells that have lost marks of senescence. In particular, the invention relates to an ex vivo method for preparing induced pluripotent stem cells (iPSCs) from a target cell population comprising cells from aged donors or senescent cells, said method comprising the steps of culturing said target cell population under appropriate conditions for reprogramming said cells into iPSCs, wherein said appropriate conditions comprises increasing expression in said target cells, of at least the following reprogramming factors: Oct4, Klf4, Sox2, c-Myc, Lin28 and, optionally Nanog.

One disclosure provides a method for determining a senescence based disorder by detection of cells with senescence specific DNA damage markers which includes the step of providing a sample with one or more cells. It also includes the steps of identifying with immunodetection the presence of activated DNA damage response proteins that are shown to be activated with senescence and identifying with immunodetection the inactivation of DNA damage response proteins that are shown to be inactive in senescence.

The invention discloses a wrinkle-removing, anti-ageing, skin-activating, restoring and whitening composition. The composition comprises the following components in percentage by weight: 15%-30% of hyaluronic acid, 25%-40% of collagen, 0.0001%-0.0009% of recombinant human epidermal growth factor, and 5%-20% of glycerol. Collagen can effectively inhibit generation of melanin and promote metabolism of skin tissue; hyaluronic acid can effectively nourish and moisturize skin, remove wrinkles and beautify looks; recombinant human epidermal growth factor can quicken dropping of senescent cells of a human body and promote reverse differentiation of the cells to generate young cells, can promote regeneration of subcutaneous collagen and recombination of fibrous tissue, improve skin elasticity and reduce skin sensitivity, and can make thick, flushing and expanding facial capillaries atrophy and get thinner and shallower, avoid pigmentation and remove facial toxin residues so as to achieve the efficacy of removing freckles, acne marks and wrinkles as well as tendering and whitening.

A method for enhancing the in vitro and in vivo lifespan of T cells is provided. A method for enhancing the life span of a T cell is provided. The method includes engineering the T cell to express exogenous ribonucleic acid (RNA), where the RNA includes a nucleic acid encoding telomerase reverse transcriptase (TERT). T cells genetically engineered to transiently express exogenous RNA which includes the coding sequence for TERT (TERT T cells) are provided. TERT T cells have one or more of the following characteristics when compared to a T cells not expressing TERT from an exogenously introducednucleotide: enhanced in vitro and in vivo proliferation, decreased number of senescent cells, and enhanced in vivo anti-cancer activity. The modified TERT T cells can be used in adoptive cell transfer to treat a subject in need thereof.

The invention discloses an in vitro efficient amplification method for human umbilical cord blood hematopoietic stem cells. The method comprises the following steps: (1) collecting umbilical cord blood, namely under aseptic conditions, drawing neonatal cord blood during full-term normal delivery or caesarean operation in a needle aspiration manner, putting the neonatal cord blood into a centrifugal tube, carrying out anticoagulation with heparin, and carrying out cryopreservation; (2) carrying out in vitro culture and amplification on umbilical cord mesenchymal stem cells; (3) preparing a bioactive factor; and (4) preparing lysate. The method disclosed by the invention has the advantages that the bioactive factor or substance does not contain any animal derived ingredient, a product with a cytobiology active function can be developed by utilizing the bioactive factor or substance, after the product acts on a human body, organism stem cells can be activated, damaged, diseased and senescent cells can be repaired or replaced, and the bioactive factor or substance has the functions of regulating cellular metabolism of an organism, enhancing immunity of the organism and delaying senescence.

This invention identifies tumor senescence genes induced by treatment with cytotoxic agents. The invention provides reagents and methods for identifying compounds that induce expression of these cellular genes and produce cellular senescence, particularly senescence in tumor cells. The invention also provides reagents that are recombinant mammalian cells containing recombinant expression constructs that express a reporter gene under the transcriptional control of a promoter for a gene the expression of which is modulated in senescent cells, and methods for using such cells to identify compounds that modulate expression of these cellular genes.

The invention provides an anti-aging drug D/S for targeting senescent cells in a tissue micro-environment and application of the anti-aging drug D/S. Combined application of dasatinib and SRT2104 is adopted, and extremely excellent effects of reduction or removal of the senescent cells in the body are achieved, so that the drug is applied to removal damaged cells which are obtained after chemotherapy or radiation treatment and other damaged cells in the tissue micro-environment, and is also applied to elimination of cells which age naturally with ages, and the survival time of the body is prolonged.

The present invention relates to an agent for use in selectively killing one or more senescent cells, wherein the agent is selected from the following: a cardiac glycoside or alglycone, a focal adhesion kinase (FAK) inhibitor, an HMG-CoA reductase inhibitor, JFD00244, Cyclosporine, Tyrphostin AG879, Cantharidin, Diphenyleneiodonium chloride, Rottlerin, 2,3-Dimethoxy-1,4-naphthoquinone, LY-367,265,Rotenone, Idarubicin, Dequalintum chloride, Vincristine, Nitazoxanide, Nitrofurazone, Temsirolimus, Eltrombopag, Adapalene, Azacyclonol, Enoxacin and Raltegravir, and pharmaceutically acceptable salts thereof. Another aspect relates to compounds for use in treating or preventing a senescence- associated disease or disorder, and methods relating thereto.

The invention provides a fluorescence quantitative in-situ hybridization (Q-FISH) method for determination of telomere length by using genomic DNA, wherein the method comprises the steps: the genomicDNA is fixed on a glass slide and then is hybridized with a telomere-specific PNA probe, and fluorescence data are collected; the method is also suitable for determination of the telomere lengths of split active and senescent cells; a plurality of telomere length parameters comprising the average telomere length, the telomere length variation and the frequency of abnormal-length telomeres can be obtained, and the defect that the telomere function is evaluated by single dependency of the average telomere length to obtain information is eliminated. The invention also provides a stronger-specificity telomere-specificity PNA probe, TTAGGG is shortened to 2 repetitions, the amount of the probe is reduced by half and a fluorescence signal is doubled. The invention also provides a telomere lengthstandard and a preparation method thereof, wherein the telomere length standard can be used for measuring the base length of each telomere and also can be used as calibration standard for different tests. If the automatic detection method is adopted, a large number of samples can be processed, and the method saves manpower compared with other methods.

The invention provides a novel exosome release related target and application thereof to monitoring and inhibiting of tumors. The invention discloses exosomes produced by senescent cells and some biomolecules involved in regulating the exosomes, and the exosomes and the some biomolecules are closely related to drug resistance and tumor prognosis after tumor chemotherapy treatment. Therefore, the invention provides a new target for inhibiting tumors and reversing tumor drug resistance, and a new marker for tumor diagnosis and prognosis evaluation.